Risks of Improper Stimulant Prescribing With Telemedicine-Only Platforms

Recently, healthcare providers adopted telemedicine as a means to remotely grant access to patients seeking treatment for attention-deficit/hyperactivity disorder (ADHD). Two significant changes occurred during COVID-19 that facilitated the growth of telemedicine and the emergence of direct-to-consumer telemedicine-only corporations treating mental health conditions. First, the Drug Enforcement Administration issued a temporary rule suspending the requirement that providers conduct an in-person…

via https://pubmed.ncbi.nlm.nih.gov/41719473/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20260302010905&v=2.19.0.post6+133c1fe